Larimar Therapeutics shares surged over 30% pre-market after the FDA granted Breakthrough Therapy Designation to its drug nomlabofusp for Friedreich ataxia. Preliminary data shows the therapy increased frataxin levels in patients. The FDA also accepted skin FXN as a surrogate endpoint, supporting the planned Biologics License Application submission.